Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation | Zendy

Joseph M. Rocco | Zendy; Christina Mallarino-Haeger | Zendy; Attiya Randolph | Zendy; Susan M. Ray | Zendy; Marcos C. Schechter | Zendy; Christa S. Zerbe | Zendy; Steven M. Holland | Zendy; Irini Sereti | Zendy

Open Access

Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation

Author(s) -

Joseph M. Rocco,

Christina Mallarino-Haeger,

Attiya Randolph,

Susan M. Ray,

Marcos C. Schechter,

Christa S. Zerbe,

Steven M. Holland,

Irini Sereti

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab1024

Subject(s) - medicine , vaccination , immunology , immune system , immune dysregulation , coronavirus , covid-19 , disease , infectious disease (medical specialty)

The development of effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5 patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research